Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Comment by PoorOpinionon Dec 11, 2017 3:51pm
288 Views
Post# 27133040

RE:RE:RE:News

RE:RE:RE:News
thesheet wrote: sounds like good news to me,(and the patients).

more patience is required on the sell on the news




When I read it what stood out as a possible negative was the response in the intravenous group. 5 out of 18 with an "objective response" sounded a little low (and vague). But honestly I dont know whether this is above or below expectations ATM. The intratumoral stuff is exciting and shows the potential for the drug but the intravenous dosing needs to work for this to be a plausible drug I would think. Clearly they are considering going with higher doses now that the first dose negative reaction is better understood.
<< Previous
Bullboard Posts
Next >>